G Diego Miralles
Overview
Explore the profile of G Diego Miralles including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
151
Followers
0
Related Specialty
Related Specialty
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tomaka F, Lefebvre E, Sekar V, Van Baelen B, Vangeneugden T, Vandevoorde A, et al.
HIV Med
. 2009 Feb;
10(5):318-27.
PMID: 19210693
Background: Darunavir (TMC114) is a new HIV protease inhibitor (PI). Design: This Phase I, randomized, open-label trial compared the effects of darunavir plus low-dose ritonavir (RTV) (darunavir/RTV) with those of...
2.
De Meyer S, Spinosa-Guzman S, Vangeneugden T, de Bethune M, Diego Miralles G
J Acquir Immune Defic Syndr
. 2008 Sep;
49(2):179-82.
PMID: 18769351
Objective: The objective of this study was to examine the potential of once-daily dosing with darunavir/ritonavir 800/100 mg in a HIV-infected, treatment-experienced patient population with no baseline darunavir resistance-associated mutations...
3.
Thompson M, DeJesus E, Richmond G, Wheeler D, Flaherty J, Piliero P, et al.
AIDS
. 2006 Jan;
20(3):397-404.
PMID: 16439873
Objective: To investigate the pharmacokinetics, safety/tolerability and antiviral activity of enfuvirtide administered once-daily (QD) versus twice-daily (BID). Design: An open-label, randomized, multiple dose, two-period crossover study comparing 180 mg enfuvirtide,...
4.
Lalezari J, Bellos N, Sathasivam K, Richmond G, Cohen C, Myers Jr R, et al.
J Infect Dis
. 2005 Mar;
191(7):1155-63.
PMID: 15747252
Background: T-1249 is a 39-amino acid synthetic peptide fusion inhibitor (FI) shown to preserve antiretroviral activity in vitro against human immunodeficiency virus (HIV) isolates that have decreased susceptibility to enfuvirtide...
5.
Short-term safety and antiretroviral activity of T-1249, a second-generation fusion inhibitor of HIV
Eron J, Gulick R, Bartlett J, Merigan T, Arduino R, Michael Kilby J, et al.
J Infect Dis
. 2004 Mar;
189(6):1075-83.
PMID: 14999611
T-1249 is a 39-aa synthetic peptide that inhibits fusion of human immunodeficiency virus (HIV) to the host target cell. A 14-day open-label, phase 1/2 dose-escalation monotherapy study of the safety...
6.
Alexander T, Ortiz G, Wellons M, Allen A, Grace 2nd E, Schweighardt B, et al.
J Acquir Immune Defic Syndr
. 2003 Dec;
34(5):475-81.
PMID: 14657757
Markers of maturation and activation were measured on peripheral CD4+ T cells in chronically HIV-1-infected patients in a randomized, controlled pilot study of structured treatment interruption (STI). Eight subjects underwent...
7.
Emergence of drug-resistant HIV-1 variants in patients undergoing structured treatment interruptions
Schweighardt B, Ortiz G, Grant R, Wellons M, Diego Miralles G, Kostrikis L, et al.
AIDS
. 2002 Nov;
16(17):2342-4.
PMID: 12441810
We report the emergence of drug-resistant viral mutations in chronically HIV-infected individual undergoing structured treatment interruptions (STI). THe protease mutations K101E and K103N were detected at the end of the...
8.
Bartlett J, Diego Miralles G, Sevin A, Silberman M, Pruitt S, Ottinger J, et al.
AIDS Res Hum Retroviruses
. 2002 May;
18(8):535-43.
PMID: 12036483
The chronically HIV-infected cellular reservoir in lymphoid tissue (LT) represents a formidable obstacle to the long-term success of antiretroviral therapy. Cytoreductive chemotherapy with cyclophosphamide (CTX) reduces cells in LT, and...
9.
Diego Miralles G, Bregman Z
Clin Infect Dis
. 1994 May;
18(5):833-4.
PMID: 8075286
No abstract available.